Recombinant and Prophylactic Treatments Boost Global Haemophilia Therapeutics Market
Haemophilia B segment will see high growth over the forecast period, finds Frost & Sullivan
11-May-2015 -
Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to ...
Frost & Sullivan
hemophilia A
hemophilia B
+2